P. Foster

发表

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

K. Yamaguchi, J. Nuss, J. Woolfrey, 2013, Journal of medicinal chemistry.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2016 .

Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).

J. Bendell, H. Hochster, K. Iizuka, 2017 .

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

K. Yamaguchi, D. J. Matthews, F. Yakes, 2014, Molecular Cancer Therapeutics.

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Stefan Westin, Brett R. Murphy, C. Daige, 2009, Journal of medicinal chemistry.

Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147

P. Foster, 2007 .

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

S. Adams, L. Molinero, J. Diamond, 2019, JAMA oncology.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.

Charles R. Holst, J. Nuss, Xiang Wu, 2012, Journal of medicinal chemistry.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

E. Van Cutsem, R. Kelley, C. Verslype, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

David C. Smith, R. Berger, R. Kurzrock, 2017, European journal of cancer.

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

J. Desai, Y. Bang, E. Kwak, 2016 .

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, Y. Bang, 2019 .

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

J. Desai, Y. Bang, Tae Won Kim, 2018 .

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2018, Journal of Thoracic Oncology.